- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2013
- Public Summary Document (PSD) July 2013 PBAC Meeting - PDF
Olmesartan medoxamil and amlodipine and hydrochlorothiazide – July 2013
Olmesartan medoxomil and amlodipine and hydrochlorothiazide 20/5/15.5 mg, 40/5/12.5 mg, 40/5/25 mg, 40/10/12.5 mg, 40/10/25 mg, Sevikar HCT®.
Last updated
8 November 2023
